Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 84Cisplatin 73Cetuximab 54Radiotherapy 41Nivolumab 31Radiotherapy, Intensity-Modulated 26Docetaxel 26Fluorouracil 23Cyclophosphamide 23Paclitaxel 22fludarabine 19Radiation 18Gemcitabine 18Carboplatin 18Magnetic Resonance Spectroscopy 16Erlotinib Hydrochloride 16durvalumab 15atezolizumab 13fludarabine phosphate 10Radiosurgery 10Specimen Handling 9Interleukin-2 9Drug Therapy 9Biopsy 9130-nm albumin-bound paclitaxel 9budigalimab 8Ipilimumab 8Bortezomib 8tremelimumab 7toripalimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Medicare Part B × Head & Neck × Clear all
NCT03474640 2024-11-22

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Completed
184 enrolled 20 charts
GastrointestinalHead & NeckSarcoma

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡